{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.1","upperLimit":"88.4","value":"71.8"},{"groupId":"OG001","lowerLimit":"26.3","upperLimit":"74.4","value":"53.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Progressive Disease (PD) according to Uniform Response Reporting Criteria for Multiple Myeloma by the International Myeloma Working Group (IMWG). Increase of 25% from lowest response value in any of the following:\n\n* Serum M- component (absolute increase must be ≥ 0.5 g/dL)\n* Urine M-component (absolute increase must be ≥ 200 mg/24 h)\n* Only in patients without measurable serum and urine M protein levels and without measurable disease by free light chain (FLC) levels, bone marrow plasma cell percentage (absolute percentage must be ≥ 10% )\n* Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas\n* Development of hypercalcemia (corrected serum calcium \\> 11.5 mg/dL) that can be attributed solely to the plasma cell proliferative disorder","dispersionType":"95% Confidence Interval","groups":[{"description":"Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.\n\nPanobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.","id":"OG000","title":"Cohort A: Maintenance Therapy"},{"description":"Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.\n\nPanobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.","id":"OG001","title":"Cohort B: Maintenance Therapy"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"at 2 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}